Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea

Study Identifier
EPI-MULT-100
CT.gov Identifier
NCT02043145
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Other
  • Movement Disorders - Other
  • Facial Aesthetics - Toxins
    • Study Drug
  • botulinum toxin Type A
    • Phase
    N/A
    Sex
    N/A
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines.
    Exclusion Criteria:
    * None.

    Protocol Summary

    This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines in clinical practice.

    Study Locations

    Location
    Status
    Location
    Seoul, Republic of Korea
    Status
    Not applicable